Kangmei Pharma | 600518 - Cash And Equivalent


Kangmei Pharma reported CNY1.23B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Akebia Therapeutics USD 155.55M 7.1M Jun/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Avita Medical AUD 10.24M 1.98M Dec/2025
Cspc Pharmaceutical CNY 6.09B 1.48B Dec/2025
Dianthus Therapeutics USD 110.55M 517.12M Jun/2026
Genomma Lab Internacional MXN 2.44B 373.92M Jun/2026
Hypermarcas BRL 2.31B 665.36M Mar/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
IQVIA Holdings USD 1.91B 38M Jun/2026
Jiangsu Hengrui CNY 40.96B 591.41M Dec/2025
Kangmei Pharma CNY 1.23B 48.16M Mar/2026
Moderna USD 1.72B 185M Jun/2026
Organon & Co USD 1.12B 542M Mar/2026
Revvity USD 1.02B 162.62M Jun/2026
Sh Fosun Pharma CNY 13.1B 1.63B Dec/2025
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Viatris USD 886.5M 917.7M Jun/2026
Wuxi Apptec CNY 35.91B 773.93M Mar/2026
Xeris Pharmaceuticals USD 121.75M 10M Jun/2026
Zz Pientze Pharmaceu CNY 1.96B 186.63M Mar/2026